Oral Anticancer Therapy : Management of Drug Interactions
Oral anticancer therapy is increasingly integrated into the care of patients with cancer. Recognition and management of drug-drug interactions (DDIs) is critical to providing efficacious and safe anticancer treatment. DDIs with QTc-prolonging agents, anticoagulants, enzyme inducers and inhibitors, antidepressants, and acid suppressants are commonly encountered with anticancer therapies. Here, we review frequently observed DDIs and outline literature-supported suggestions for their management.
| Errataetall: |
CommentIn: J Oncol Pract. 2019 Feb;15(2):91-92. - PMID 30763201 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Journal of oncology practice - 15(2019), 2 vom: 14. Feb., Seite 81-90 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rogala, Britny G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 18.03.2020 Date Revised 18.03.2020 published: Print CommentIn: J Oncol Pract. 2019 Feb;15(2):91-92. - PMID 30763201 Citation Status MEDLINE |
|---|
| doi: |
10.1200/JOP.18.00483 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM293887616 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM293887616 | ||
| 003 | DE-627 | ||
| 005 | 20231225080306.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JOP.18.00483 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0979.xml |
| 035 | |a (DE-627)NLM293887616 | ||
| 035 | |a (NLM)30763198 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rogala, Britny G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oral Anticancer Therapy |b Management of Drug Interactions |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2020 | ||
| 500 | |a Date Revised 18.03.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: J Oncol Pract. 2019 Feb;15(2):91-92. - PMID 30763201 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Oral anticancer therapy is increasingly integrated into the care of patients with cancer. Recognition and management of drug-drug interactions (DDIs) is critical to providing efficacious and safe anticancer treatment. DDIs with QTc-prolonging agents, anticoagulants, enzyme inducers and inhibitors, antidepressants, and acid suppressants are commonly encountered with anticancer therapies. Here, we review frequently observed DDIs and outline literature-supported suggestions for their management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Charpentier, Margaret M |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Michelle K |e verfasserin |4 aut | |
| 700 | 1 | |a Landolf, Kaitlin M |e verfasserin |4 aut | |
| 700 | 1 | |a Hamad, Lamya |e verfasserin |4 aut | |
| 700 | 1 | |a Gaertner, Kelly M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of oncology practice |d 2005 |g 15(2019), 2 vom: 14. Feb., Seite 81-90 |w (DE-627)NLM185987591 |x 1935-469X |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2019 |g number:2 |g day:14 |g month:02 |g pages:81-90 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JOP.18.00483 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2019 |e 2 |b 14 |c 02 |h 81-90 | ||